AstraZeneca, Accord Settle Seroquel XR Patent Spat

Law360, New York (October 5, 2011, 5:34 PM EDT) -- Pharmaceutical giant AstraZeneca PLC announced Wednesday that it had reached a patent settlement over its antipsychotic drug Seroquel XR with Accord Healthcare Ltd. and parent company Intas Pharmaceuticals Ltd., just a week after reaching a similar deal with Handa Pharmaceuticals LLC.

Accord was one of several drug company defendants sued by AstraZeneca over attempts to market generic forms of Seroquel. Under the settlement, Intas and Accord have agreed not to sell a generic form of the extended-release tablet used to treat depression, bipolar disorder and schizophrenia...
To view the full article, register now.